Background {#sec0001}
==========

Central nervous system (CNS) manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection include encephalopathy, encephalitis, meningitis, acute disseminated encephalomyelitis, and stroke,[@bib0001] both as a result of direct viral invasion of the central nervous system[@bib0002], [@bib0003], [@bib0004], [@bib0005] and as a consequence of critical illness and systemic infection.[@bib0006] Coronavirus disease 2019 (COVID-19) may also cause significant changes in endothelial morphology, including disruption of intercellular junctions, cell swelling, and a loss of contact with the basal membrane.[@bib0007] However, posterior reversible encephalopathy syndrome (PRES), which may result from such endothelial dysfunction, has rarely been reported in patients with COVID-19.[@bib0008], [@bib0009], [@bib0010], [@bib0011] The diverse etiologies and risk factors of PRES in this unique population warrant close examination, as they may elucidate strategies to prevent or treat the syndrome in select patients with COVID-19.

Methods {#sec0002}
=======

This study protocol was approved by the Boston Medical Center\'s Institutional Review Board. Two cases were identified through surveillance of patients admitted to the neurocritical care service between April 1, 2020 and June 24, 2020 with positive nasopharyngeal swab testing for SARS-CoV-2 and a clinical diagnosis of PRES.

A literature review for published cases of PRES in patients with COVID-19 was conducted on July 20, 2020 by searching PubMed and Medline using the terms "posterior reversible encephalopathy syndrome AND COVID" and "PRES AND COVID".

Results {#sec0003}
=======

Case 1 {#sec0004}
------

A previously healthy 61-year-old woman presented with one week of dyspnea, headaches, fever, and cough. She was diagnosed with COVID-19 based on a positive nasopharyngeal PCR for SARS-CoV-2 and was treated with remdesivir and anakinra. Her hospital course was complicated by worsening respiratory failure requiring intubation on hospital day 5, subsequent proning for respiratory distress syndrome, ventilator dyssynchrony requiring significant sedation and periodic paralysis, and septic shock with hypotension requiring vasopressors. On hospital day 15, a head CT was obtained because of persistently poor mental status in spite of weaning sedation and revealed significant posterior cortical paramedian hypodensity consistent with cerebral edema ([Fig. 1](#fig0001){ref-type="fig"} A). Blood pressure range was 152--187/79--98 mmHg, with no metabolic derangements. CT venogram showed no evidence of venous sinus thrombosis. In order to conserve personal protective equipment and limit healthcare worker exposure and risk, a lumbar puncture was not performed.Fig. 1Patient 1: (a) Head CT demonstrating hypodensities involving the subcortical white matter of the bilateral parietal and occipital lobes. (b) Hyperintensities in the same anatomic distribution as the CT on T2-weighted MRI sequences. (c) Multiple foci of susceptibility artifact in the right parietal and frontal lobes (arrows) on susceptibility-weighted MRI sequences. Patient 2: (d) CT hypodensities involving the cortical and subcortical white matter of the bilateral occipital and temporal lobes. (e) Hyperintensities in the same anatomic distribution as the CT on T2-weighted MRI sequences. (f) Multiple foci of susceptibility artifact in the right.Fig 1:

A subsequent brain MRI on hospital day 18 revealed symmetric white matter T2 hyperintense signal abnormalities involving the parietal and occipital lobes without diffusion restriction consistent with PRES, as well as a focus of susceptibility artifact in the right frontal lobe ([Fig. 1](#fig0001){ref-type="fig"}B-C). On hospital day 18, she had a clinical seizure characterized by rightward gaze deviation and right arm and leg shaking. She was treated with levetiracetam and valproic acid. Subsequent 24 h continuous video electroencephalography (EEG) revealed rare bursts of repetitive sharp waves and spikes noted over the right hemisphere with a broad field, more prominent over the right frontal-parietal region with no clear ictal evolution. She was extubated on hospital day 21, but was re-intubated on hospital day 24 because of worsening hypoxemia, ultimately undergoing a tracheostomy. Her mental status improved over the subsequent weeks. At time of discharge on hospital day 48, she was alert, oriented, and following commands consistently.

Case 2 {#sec0005}
------

A 52-year-old woman with a history of HIV infection (CD4+ lymphocyte count 699/µL, viral load undetected) presented with fever and respiratory distress requiring intubation in the emergency department. Admission labs were remarkable for hyperglycemia to 450 mg/dL with an anion gap of 23 mEq/L, and her course was complicated by oliguric renal failure with a maximum creatinine of 4.33 mg/dL requiring continuous hemodialysis. She was diagnosed with COVID-19 based on a positive nasopharyngeal PCR for SARS-CoV-2 but did not receive specific therapies for COVID-19 because of her renal failure. Her respiratory status continued to worsen, and she underwent proning for respiratory distress syndrome. She subsequently developed ventilator dyssynchrony requiring significant sedation and periodic paralysis. Tracheostomy was placed on hospital day 23 because of an inability to extubate, and her course was further complicated by septic shock with hypotension requiring vasopressors.

On hospital day 34, she had a 2 min clinical seizure characterized by leftward gaze deviation and generalized tonic-clonic movements. Blood pressure range was 140--180/70--97 mmHg. Her head CT revealed bilateral occipital hypodensities ([Fig. 1](#fig0001){ref-type="fig"}D). A 24 h continuous video EEG revealed a reactive and continuous background without epileptiform discharges. Brain MRI on hospital day 35 revealed diffuse T2 hyperintensities involving the white matter of the bilateral parietal, occipital, frontal, and temporal lobes, with partial sulcal effacement. Similar to case 1, there were punctate microhemorrhages in the temporal and occipital lobes. ([Fig. 1](#fig0001){ref-type="fig"}E-F). Cerebrospinal fluid (CSF) analysis revealed an elevated protein of 95 mg/dL, glucose 78 mg/dL, elevated total nucleated cell count of 28/µL (89% polymorphonuclear), red blood cell count of 223/µL, and negative infectious studies including a meningitis and encephalitis PCR panel and a cryptococcal antigen. Her mental status gradually improved over the next several days. On hospital day 43, 9 days after onset of symptoms attributable to PRES, she was alert and oriented and began to follow commands consistently. Follow-up head CT demonstrated significant improvement in the hypodensities of the bilateral occipital, parietal, temporal and frontal lobes.

Literature search {#sec0006}
-----------------

We found 13 cases of PRES in patients with COVID-19 in the literature.[@bib0008] ^,^ [@bib0009] ^,^ [@bib0011], [@bib0012], [@bib0013], [@bib0014] There was an additional case of PRES identified via virtuopsy (post-mortem imaging) but this was excluded from our results due to limited clinical details.[@bib0010] The included patients all had positive nasopharyngeal PCR for SARS-CoV-2. Relevant clinical details for these cases are summarized in [Table 1](#tbl0001){ref-type="table"} along with the 2 patients in our series for comparison.Table 1Summary of 13 cases of posterior reversible encephalopathy syndrome in patients with COVID-19. Patients 1 and 2 are described in this case series while patients 3 through 13 are cases reported in the literature. CT: computed tomography; CTA: computer tomography angiography; FLAIR: fluid attenuated inversion recovery; HIV: human immunodeficiency virus; ICU: intensive care unit; MRI: magnetic resonance imaging; PRES: posterior reversible encephalopathy syndrome; SWI: susceptibility weighted imaging.Table 1:Patient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8Patient 9Patient 10Patient 11Patient 12Patient 13**Age**61524867385867646473657474**Gender**FemaleFemaleMaleFemaleMaleMaleFemaleFemaleMaleMaleFemaleFemaleMale**Comorbidities**NoneHIVObesityHypertension, diabetes, coronary artery disease, gout, asthmaNoneHyperlipidemiaHypertension, diabetes, obesityHypertension, gastroesophageal reflux disease, hyperuricemia, dyslipidemia, obstructive sleep apnea, paroxysmal atrial fibrillationUnknown, none reportedUnknown, none reportedHypertension, diabetesHypertension, diabetes, hyperlipidemiaIgG kappa multiple myeloma**Blood pressure (mm Hg)**152-187/79-98140-180/70-9770-180/30-90115-178/72-83"high levels for few hours"86--189/52--12279-193/44-97150/70 on admission, no others reportedSBP 187, MAP 128 (maximum values)SBP 212, MAP 135 (maximum values)SBP 180, MAP 138 (maximum values)SBP 237, MAP 150 (maximum values)SBP 140-150 at the time of diagnosis**Presentation of COVID-19**Fever, dyspnea, cough, malaiseFever, dyspnea, chest painFever, dyspnea, coughAltered mental status (no respiratory symptoms)Fever, dyspneaFever, dry cough, malaiseFever, dyspnea, myalgia, vomiting, diarrheaFever, dyspneaUnknown, not describedDyspnea, coughDyspnea, coughFever, coughFever, dry cough**Mechanical Ventilator Status**(+)(+)(+)(-)(+)(+)(+)(+)(+)(+)(+)(+)Unknown, not reported**Chest Radiologic Findings**CT chest with peripheral diffuse ground glass opacities. No pleural effusions.Chest X-ray with bilateral diffuse airspace opacitiesUnknown, not reportedCT chest with bilateral, multifocal ground-glass opacitiesCT chest with bilateral multiple, multilobar, peripheral ground glass opacificationsUnknown, not reportedUnknown, not reportedChest X-ray with reduction of parenchymal transparency in the basal region of right lungUnknown, not reportedUnknown, not reportedUnknown, not reportedUnknown, not reportedUnknown, not reported**Treatment for COVID-19**Anakinra 200mg IV q12h x 3 days Remdesivir 200mg IV followed by 100mg IV x 4 daysNone administeredsUnknown, none reportedUnknown, none reportedHydroxychloroquine 400mg followed by 200mg/d x 4 days Azithromicin 500mg/d Osetalmivir 150mg/dTocilizumab 400mg IV Hydroxychloroquine (dose not reported) Azithromicin (dose not reported)Hydroxychloroquine (dose not reported) Azithromicin (dose not reported)Unknown, none reportedHydroxchloroquine (dose not reported)Hydroxychloroquine (dose not reported)Hydroxychloroquine (dose not reported)Hydroxychloroquine (dose not reported), tocilizumabHydroxychloroquine 200 mg q12, lopinavir / ritonavir 400/100 mg q12, dexamethasone 20 mg q12**Symptoms attributable to PRES**Altered mental statusAltered mental status and clinical seizureAltered mental statusAltered mental statusBilateral vision loss, apathic, impaired ability to follow commandsAltered mental statusAltered mental statusAltered mental status, blurred visionAltered mental status, global aphasiaLeft gaze preference, subclinical seizuresStuporousPersistent confusion with intermittent agitationClonic movement of the left limb, focal motor seizures**MRI findings**T2 hyperintensities in parietal and occipital lobes; SWI with focus of susceptibility artifact in right frontal lobeT2 hyperintensities involving right side of splenium of corpus callosumT2/FLAIR hyperintensities in posterior regions; SWI with extensive petechial hemorrhages throughout corpus callosumRestricted diffusion with associated edema most extensive in posterior regions; SWI with extensive superimposed hemorrhages in parieto-occipital regionT2/FLAIR hyperintensities and diffusion restriction on DWI in bilateral, especially left occipital, frontal cortical white matter and splenium of corpus callosumT2/FLAIR hyperintensities in subcortical white matter of bilateral occipital and posterior temporal lobes; SWI with subarachnoid hemorrhageT2/FLAIR hyperintensities in subcortical white matter of right occipital lobe and left cerebellar hemisphere; SWI with petechial hemorrhageT2/FLAIR vasogenic edema; GRE with right temporal lobe hypointensityT2/FLAIR hyperintensities include the white matter of the bilateral occipital lobes, thalamus, and internal capsuleT2/FLAIR bilateral subcortical occipital lobe hyperintensity compatible with vasogenic edemaT2/FLAIR mild subcortical bilateral occipital lobe edemaT2/FLAIR hyperintensities in the white matter of the occipital lobes susceptibility weighted images with signal loss in the right occipital lobeT2/FLAIR hyperintensities in the parietal lobe and right frontal lobe white matter**Cerebrovascular Imaging**CTA/CTV, normal vasculatureNoneNoneNoneNoneNoneNoneCTA without vascular malformation, posterior vessel caliber suggestive of vasoconstrictionNoneNoneNoneNoneNone**Risk factors for PRES**SepsisHIV Renal failureNone mentionedHypertensionNone mentionedHypertension SepsisAcute kidney injury requiring hemodialysis SepsisNone mentionedNone mentionedNone mentionedNone mentionedNone mentiontedMultiple myeloma**Onset of PRES from hospitalization**Less than 15 days34 days18 days0 days5 days26 days25 days25 daysNot reported6 weeksNot reportedNot reported15 days**SOFA**67Insufficient dataInsufficient dataInsufficient dataInsufficient dataInsufficient dataInsufficient dataInsufficient dataInsufficient dataInsufficient dataInsufficient dataInsufficient data**Outcome**Mental status gradually improved, discharged 33 days after onset of symptoms attributable to PRESMental status gradually improved, became interactive and started following commands 9 days after onset of symptoms attributable to PRESMental status gradually improved, transferred from ICU to medical floor six days from onset of symptoms attributable to PRESMental status gradually improved and dischargedVisual impairment resolved two days after onset following corticosteroid administration, neurocognitive assessment on day 10 of hospitalization was normal, brain MRI two weeks after symptom onset showed complete resolution of prior lesions\
Mentation slowly improved to baseline, discharged 7 days after onset of symptoms attributable to PRESMentation slowly improved to nearly baseline, discharged 22 days after onset of symptoms attributable to PRESAlert, fully oriented; blurry vision normalizedAlert, oriented, inattentive, right homonymous hemianopsiaAlert, following commands, no focal neurological deficitsMild cognitive deficit, no focal neurological deficitAlert and oriented to person and time (not to place), consistently following commandsNot reported**Reference**n/an/aFranceschi et al (2020)[@bib0010]Franceschi et al (2020)[@bib0010]Kaya et al (2020)[@bib0007]Kishfy et al (2020)[@bib0008]Kishfy et al (2020)[@bib0008]Cariddi et al (2020)[@bib0012]Parauda et al, (2020)[@bib0013]Parauda et al, (2020)[@bib0013]Parauda et al (2020)[@bib0013]Parauda et al (2020)[@bib0013]Gomez-Enjuto et al (2020)[@bib0014]

Discussion {#sec0007}
==========

We cared for 2 patients with COVID-19 and PRES at our institution and identified additional cases through a literature search, finding variable risk factors for developing the syndrome. Although the exact mechanisms underlying PRES are unclear, contributing factors are thought to include hypertension with subsequent cerebral hyperperfusion and endothelial dysfunction.[@bib0015] SARS-CoV-2 has been found to bind directly to angiotensin-converting enzyme 2 receptors, which can dysregulate the endothelial layer, increase blood pressure, and disrupt cerebral blood flow autoregulation.[@bib0016] The mechanism by which COVID-19 may be associated with PRES is unclear, although it is notable that neuropathological studies of patients with COVID-19 and central nervous system dysfunction have identified only hypoxic changes without specific brain changes attributable to the virus.[@bib0017]

By contrast to the majority of published cases of PRES,[@bib0008] ^,^ [@bib0009] the patients described here had relatively modest blood pressure fluctuations before developing the syndrome. Similar to guidance offered by other authors,[@bib0008] we advocate for tight blood pressure control in patients with COVID-19 and risk factors for PRES, including renal failure, uncontrolled hypertension, or HIV infection. Two patients who developed PRES in the setting of COVID-19 were treated experimentally for the infection with interleukin inhibitors, one with the interleukin-6 inhibitor tocilizumab and one with the interleukin-1 inhibitor anakinra, which have known effects on endothelial function.[@bib0018], [@bib0019], [@bib0020] In particular, the interleukin-6 inhibitor tocilizumab has been described in association with PRES.[@bib0021] Our findings suggest that caution may be warranted when considering interleukin inhibitors to treat COVID-19 in patients with underlying PRES risk factors, that anakinra may also be associated with an increased risk of PRES in patients with COVID-19, and that these agents should be discontinued if PRES is diagnosed.

One of the patients presented here also had well-controlled HIV. Multiple reports in the literature describe PRES in HIV-infected patients, most often in those with advanced immunodeficiency, though it has been rarely described in patients with well-controlled HIV.[@bib0022], [@bib0023], [@bib0024], [@bib0025] Possible mechanisms include impaired cerebrovascular reactivity even in virally suppressed patients and long-term exposure to antiretroviral therapies that may lead to mitochondrial damage in endothelial cells.[@bib0025] The HIV-infected patient presented here had a CSF profile with elevated protein and neutrophilic pleocytosis. The latter finding is rare in PRES and may be associated with a higher risk of ischemic or hemorrhagic events, consistent in this case with the small area of restricted diffusion on imaging.[@bib0026]

The majority of patients had severe respiratory manifestations of COVID-19 requiring intensive care, with just one patient (Patient 4)[@bib0011] whose primary manifestation of COVID-19 was altered mental status secondary to PRES. Although chest CT findings were concerning for viral pneumonia, she had subclinical respiratory involvement, suggesting that development of PRES is possible without obvious pulmonary manifestations, and that COVID-19 should be considered in patients presenting with PRES without other obvious risk factors.

Five of 7 patients had foci of susceptibility artifact on imaging consistent with various degrees of hemorrhage. In general, PRES is associated with hemorrhage at an estimated rate of 10-30% in patients. Risk factors for developing hemorrhage include bone marrow or solid-organ transplantation and coagulopathy.[@bib0027] ^,^ [@bib0028] Reversible cerebral vasoconstriction syndrome, which shares findings of blood-brain barrier breakdown and cerebral edema with PRES, has also been described in association with both subarachnoid and parenchymal hemorrhage.[@bib0029] ^,^ [@bib0030] Patients 1 and 8 underwent computed tomography angiography (CTA) of the head and neck to evaluate for underlying vascular abnormalities with no alternative etiologies of hemorrhage found. Patients 2, 3, 4, 6, 7, 8, and 12 all had evidence of hemorrhage on MRI susceptibility sequences but no additional work-up was performed to evaluate for alternative etiologies of hemorrhage. Our observations suggest that hemorrhage may be more likely seen with PRES in patients with COVID-19, but additional study is required to determine the clinical significance of this finding.

Although hemorrhage and cytotoxic edema are risk factors for poor outcome in PRES,[@bib0031] all seven patients described here had marked clinical recovery. In general, 70--90% of patients with PRES have clinical recovery and resolution of edema on neuroimaging.[@bib0032] It is unclear if patients with COVID-19 may have a higher likelihood of a favorable outcome following PRES due to its potentially distinct pathophysiology.

Conclusions {#sec0008}
===========

Similar to other reports on neurologic complications of COVID-19, ours is limited by a lack of long-term follow-up. It is important, however, to describe cases early to add to the scarce literature on central nervous system injury potentially related to COVID-19. Here, we describe the diverse presentations, risk factors, and outcomes of PRES in patients with COVID-19. Based on these cases, we advocate for tight blood control for patients with COVID-19 and risk factor for PRES, and advise caution regarding the use of interleukin inhibitors in these patients. We also offer hope that COVID-associated PRES may have high likelihood of clinical recovery.
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